E-ISSN 2149-388X | ISSN 2149-0430
 
2025, Vol: 11, Issue: 1
11 / 1Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Cover Letter
License Agreement
Title Page

Case Report 


Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?

Suleyman Karakose, Ayse Zeynep Bal, Selman Unverdi, Murat Duranay.


Abstract
Background: Fluid and electrolyte disturbances, especially hyponatremia are common complications after pituitary surgeries. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the leading cause of hyponatremia in hospitals. Fluid restriction is the first step in treatment of SIADH. In rare cases vasopressin receptor inhibitors might be useful for medical treatment.
Case Presentation: In this paper, we present a case of SIADH after a pituitary surgery with an unpredictable effect of tolvaptan.
Conclusion: Tolvaptan is the most preferred agent for the treatment of SIADH nowadays. However tolvaptan might cause unpredictable situations in the course of treatment that clinicians must be very careful and in close follow
up the patient.

Key words: Hypernatremia, hyponatremia, pituitary surgery, SIADH, tolvaptan


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Suleyman Karakose
Articles by Ayse Zeynep Bal
Articles by Selman Unverdi
Articles by Murat Duranay
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Karakose S, Bal AZ, Unverdi S, Duranay M. Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?. Ulutas Med J. 2016; 2(3): 154-156. doi:10.5455/umj.20160703095035

Web Style

Karakose S, Bal AZ, Unverdi S, Duranay M. Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?. https://www.ulutasmedicaljournal.com/?mno=232578 [Access: March 15, 2025]. doi:10.5455/umj.20160703095035

AMA (American Medical Association) Style

Karakose S, Bal AZ, Unverdi S, Duranay M. Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?. Ulutas Med J. 2016; 2(3): 154-156. doi:10.5455/umj.20160703095035


Vancouver/ICMJE Style

Karakose S, Bal AZ, Unverdi S, Duranay M. Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?. Ulutas Med J. (2016), [cited March 15, 2025]; 2(3): 154-156. doi:10.5455/umj.20160703095035


Harvard Style

Karakose, S., Bal, . A. Z., Unverdi, . S. & Duranay, . M. (2016) Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?. Ulutas Med J, 2 (3), 154-156. doi:10.5455/umj.20160703095035


Turabian Style

Karakose, Suleyman, Ayse Zeynep Bal, Selman Unverdi, and Murat Duranay. 2016. Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?. THE ULUTAS MEDICAL JOURNAL, 2 (3), 154-156. doi:10.5455/umj.20160703095035


Chicago Style

Karakose, Suleyman, Ayse Zeynep Bal, Selman Unverdi, and Murat Duranay. "Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?." THE ULUTAS MEDICAL JOURNAL 2 (2016), 154-156. doi:10.5455/umj.20160703095035


MLA (The Modern Language Association) Style

Karakose, Suleyman, Ayse Zeynep Bal, Selman Unverdi, and Murat Duranay. "Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?." THE ULUTAS MEDICAL JOURNAL 2.3 (2016), 154-156. Print. doi:10.5455/umj.20160703095035


APA (American Psychological Association) Style

Karakose, S., Bal, . A. Z., Unverdi, . S. & Duranay, . M. (2016) Is Tolvaptan in the Treatment of SIADH Following Pituitary Surgery a Right Choice?. THE ULUTAS MEDICAL JOURNAL, 2 (3), 154-156. doi:10.5455/umj.20160703095035


Author LoginReviewer LoginAbout PublisherOpen Access PolicyEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessAuthor's Rights and ObligationsPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesDigital Archiving & Preservation PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About THE ULUTAS MEDICAL JOURNAL

The Ulutas Medical Journal (UMJ) is a 3 monthly (quarterly), open access, double-blind peer-reviewed, an international journal. Writing a research pap ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Journal Owner
HAYRİYE ZEHRA ULUTAŞ
Phone: +90 (532) 165 96 39​
E-mail: zehrakenanoglu@hotmail.com​
Address: Alaattin Mah. 30. Ada sok. D11 Blok
No:4 Gungor Uydukent Sitesi  Antakya/HATAY

Editor-In-Chief
KEMAL TURKER ULUTAS, MD, Assc. Prof.
Phone: + 90 (555) 491 35 59​
E-mail: drkemalturker@gmail.com
Address: Alaattin Mah. 30. Ada sok. D11 Blok
No:4 Gungor Uydukent Sitesi  Antakya/HATAY

Publisher Information
SCOPEMED Publishing Co. - TURKEY​
E-mail: scopemed@scopemed.org
Web: https://www.scopemed.com/

 

We welcome your submissions, suggestions, comments, or questions. To reach us, please use one of the methods provided on this page or Email us at ulutasmedicaljournal@gmail.com​

We will respond within 48 to 72 hours.